50-32-233. Exempt anabolic steroid products. The following anabolic steroid-containing compounds, mixtures, or preparations are exempt from this chapter:
(1) androgyn L.A.;
(2) andro-estro 90-4;
(3) depandrogyn;
(4) DEPO-T.E.;
(5) deptestrogen;
(6) duomone;
(7) duratestrin;
(8) duo-span II;
(9) estratest;
(10) estratest HS;
(11) pan estra test;
(12) premarin with methyltestosterone;
(13) synovex H pellets in process;
(14) synovex H pellets in process granulation;
(15) test-estro cypionates;
(16) testagen;
(17) testosterone cyp 50 estradiol cyp 2;
(18) testosterone, cypionate-estradiol, cypionate injection;
(19) testosterone, enanthate-estradiol, valerate injection; and
(20) tilapia sex reversal feed (investigational).
History: En. Sec. 7, Ch. 113, L. 1997.
Structure Montana Code Annotated
Chapter 32. Controlled Substances
Part 2. Scheduling of Dangerous Drugs
50-32-201. General criteria to be considered
50-32-202. Designation of drug as dangerous drug
50-32-203. Effect of rescheduling under federal law
50-32-204. Immediate precursors
50-32-205. Nonprescription drugs not to be scheduled
50-32-206. Use of names of scheduled drugs
50-32-207. Order forms for drugs in Schedules I and II
50-32-208. Prescription and medical requirements for scheduled drugs -- penalty
50-32-209. Republication of schedules
50-32-210. through 50-32-220 reserved
50-32-221. Criteria for placement of drug in Schedule I
50-32-222. Specific dangerous drugs included in Schedule I
50-32-223. Criteria for placement of drug in Schedule II
50-32-224. Specific dangerous drugs included in Schedule II
50-32-225. Criteria for placement of drug in Schedule III
50-32-226. Specific dangerous drugs included in Schedule III
50-32-227. Board authorized to exempt certain compounds, mixtures, or preparations from Schedule III
50-32-228. Criteria for placement of drug in Schedule IV
50-32-229. Specific dangerous drugs included in Schedule IV
50-32-230. Board authorized to exempt certain compounds, mixtures, or preparations from Schedule IV
50-32-231. Criteria for placement of drug in Schedule V